Infusion Timing for Lung and Head & Neck Cancers

(TIMED Trial)

This trial explores whether the time of day for administering immunotherapy affects treatment effectiveness for certain cancers. It targets patients with advanced or metastatic non-small cell lung cancer (NSCLC) and those with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC). Participants receive treatment either in the morning or afternoon to determine if timing influences outcomes like survival and treatment response. Those with NSCLC or HNSCC eligible for PD-1 or PD-L1 inhibitor therapy (a type of immunotherapy) might be suitable candidates, particularly if their condition impacts daily activities. As a Phase 2 trial, this research measures treatment effectiveness in an initial, smaller group, allowing participants to contribute to significant findings.

If you are currently using steroids like prednisone at a dose of 10 mg or more, you will need to stop taking them at least 7 days before starting the treatment. Other medications are not specifically mentioned, so it's best to discuss with the study team.

Research has shown that PD-1/PD-L1 inhibitors are generally safe for patients with non-small cell lung cancer (NSCLC). A review of clinical trials found serious side effects in about 16.7% of patients, with a small number (2.5%) experiencing drug-related deaths. While serious side effects can occur, they are not very common.

For head and neck squamous cell carcinoma (HNSCC), studies indicate that PD-1 inhibitors are also generally safe. Reviews have examined these drugs and found them effective and safe for this type of cancer. Although side effects can occur, they are usually manageable.

Researchers are excited about this trial because it explores whether the timing of administering PD-1 and PD-L1 inhibitors can enhance their effectiveness in treating lung and head & neck cancers. Unlike standard treatments that don't consider the time of day, this trial tests if giving these drugs before noon or after 3 PM could impact how well they work. By understanding how timing influences treatment outcomes, this study could pave the way for more personalized and effective cancer therapies.

This trial will evaluate the timing of PD-1 and PD-L1 inhibitor infusions for treating certain cancers, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Studies have shown that these inhibitors effectively treat these cancers. For NSCLC, these treatments can extend survival and improve response, with one study finding that 24.3% of patients responded to these inhibitors, achieving an average survival time of 14.9 months. For HNSCC, research indicates these inhibitors can effectively combat tumors, with response rates ranging from 16% to 40% in some studies. This evidence suggests that PD-1 and PD-L1 inhibitors could be a promising treatment option for patients with these cancers. Participants in this trial will receive treatment either before 12:00 PM or after 3:00 PM to assess the impact of infusion timing.²³⁴⁶⁷